Clinical trial: NCT03502330
Section: Purpose of Research
Subsections: Continuing Treatment Beyond Progression Invitation To Participate And Description Of Project

All parts of the informed consent that you have signed before for the main study remain valid, as does your consent to it, except any that are specifically revised by this document.
Clinical trial: NCT03502330
Section: Voluntary Participation
Subsections: Consent For Continued Participation In A Research Project Yale University School Of Medicine - Yale-New Haven Hospital

Study Title: A Phase I/Ib Study of APX005M in Combination with Nivolumab and Cabiralizumab in Patients with Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD-1/PD-L1 Therapy Principal Investigator: Harriet Kluger, MD Principal Investigator's Phone Number: 203-200-6622 24-Hour Phone Number: 203-200-6622 Principal Investigator's Mailing Address: PO BOX 20856, New Haven, CT 06520 Funding Source: Bristol Myers Squibb and Apexigen, Inc.